INMB | Inmune Bio, Inc. |
Biological Products (no Diagnostic Substances) |
Book value per $ invested | $ 0.49 |
Leverage | 26.73% |
Market Cap | $ 79.7m |
PE | 0.00 |
Dividend Yield | 0.00% |
Profit | $ -41.1m |
Margin | 3783.98% |
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on reprogramming the patients innate immune system to treat cancer, Alzheimers disease, and nonalcoholic steatohepatitis. The company is headquartered in La Jolla, California.